Trials / Terminated
TerminatedNCT00327470
An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD
A 102-Week, Open Label, Multicenter Trial To Investigate The Efficacy Of Macugen For The Preservation Of Visual Function In Subjects With Neovascular Age-Related Macular Degeneration (AMD) And To Assess The Benefit Of Treating Early Choroidal Neovascularization (CNV).
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 288 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the benefits of treating subjects with neovascular age-related macular degeneration (AMD) at an earlier stage of choroidal neovascularization (CNV) as compared to those with established CNV. Additionally, the study would like to determine the efficacy of Macugen in preserving visual function in those subjects having CNV secondary to neovascular AMD.
Detailed description
A decision was made by the sponsor (08 May 2009) to terminate this study early; the study had achieved the primary objective prior to termination. This study was not terminated due to safety reasons.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegaptanib Sodium 0.3 mg | Pegaptanib Sodium dosed every 6 weeks in affected eye. |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2006-05-18
- Last updated
- 2012-04-04
- Results posted
- 2010-12-17
Locations
58 sites across 15 countries: Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Italy, Poland, Portugal, Spain, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT00327470. Inclusion in this directory is not an endorsement.